高级别胶质瘤切除前活检率:全国数据库分析
本研究利用大型商业保险数据库回顾性分析2006至2022年间接受切除手术并在术后90天内接受放疗和替莫唑胺治疗的高级别胶质瘤成人患者,发现3051例切除患者中106例(3.5%)在切除前60天内接受了额外活检手术。切除前活检的可能性随年龄增长而降低(每增加5岁,OR 0.93 [95% CI 0.87-0.99];p=0.04),且多数活检在非高容量中心进行。
要点
- 高级别胶质瘤切除前60天内活检率为3.5%。
- 年龄较大者切除前活检可能性较低(每5岁OR 0.93)。
- 93.1%的切除前活检在非高容量中心完成。
核心结论
- 高级别胶质瘤患者切除前额外活检手术的比例较低(3.5%)。
- 该研究为切除前活检率提供了基线,未来在研究性药物开发需治疗前基线标本的背景下,切除前活检可能更常见。
研究设计与样本
- 回顾性队列研究,使用大型私人健康保险数据库。
- 纳入2006至2022年间接受开颅切除高级别胶质瘤并在术后90天内接受放疗和替莫唑胺治疗的成人患者。
- 共纳入3051例接受切除的患者。
主要发现
- 106例(3.5%)患者在切除前60天内接受了额外活检手术。
- 切除前活检的可能性随年龄增长而降低(每增加5岁,OR 0.93 [95% CI 0.87-0.99];p=0.04)。
- 接受活检的患者显著更年轻(p=0.02)。
- 东北地区切除前活检率最高(4.1%,11/267)。
- 大多数(93.1%,94/101)切除前活检在非高容量中心进行,其中24.5%(23/94)随后在高容量中心接受切除。
临床怎么用
- 对于高级别胶质瘤拟行切除的患者,可参考此基线评估不必要的诊断性活检风险。
- 年轻患者切除前活检可能性较高,临床决策时需综合考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In cases of high-grade glioma that ultimately proceed to resection, a purely diagnostic biopsy might be unnecessary and add undue risk and cost. The frequency of resection following biopsy in a short time frame has not been reported among patients with high-grade glioma using a nationwide database. The objective of this study was to determine the occurrence rate of resection within 60 days of biopsy among patients with high-grade glioma and to determine if this occurrence is associated with patient or hospital characteristics. METHODS: This retrospective cohort study used a large private health insurance database to identify adult patients who underwent craniotomy for resection of high-grade glioma and received radiation treatment and temozolomide within 90 days of surgery from 2006 to 2022. This patient cohort was also queried for patients who underwent surgery for biopsy within the 60 days preceding craniotomy. The patient and hospital-related factors associated with biopsy within 60 days prior to resection were then examined. RESULTS: A total of 3051 patients who underwent resection of high-grade glioma were included; 106 patients (3.5%) underwent additional surgery for biopsy within 60 days prior to resection. The likelihood of undergoing additional surgery for biopsy prior to resection decreased with increasing age (in 5-year increments, OR 0.93 [95% CI 0.87-0.99]; p = 0.04). Patients who underwent biopsy were significantly younger (p = 0.02). The Northeast region had the highest rate of preresection biopsies (4.1%, 11/267). Most patients (93.1%, 94/101) underwent preresection biopsy at non-high-volume centers, and 24.5% (23/94) of these patients subsequently underwent resection at a high-volume center. CONCLUSIONS: A low proportion of patients with high-grade glioma underwent additional surgery for biopsy prior to resection. This finding provides a baseline as preresection biopsy might become more common in the context of investigational drug development requiring pretreatment baseline specimens.
引用
- Howard SD, Liu T, Hsu JY, et al. Rate of biopsy prior to resection among patients with high-grade glioma: a nationwide database analysis. J Neurosurg. 2025. PMID: 41202302. doi:10.3171/2025.6.JNS25618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。